Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia 7Lymphoma, Non-Hodgkin 6Burkitt Lymphoma 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Blast Crisis 4Waldenstrom Macroglobulinemia 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Dendritic Cell Sarcoma, Interdigitating 3Congenital Abnormalities 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Methylprednisolone 2fish oil triglycerides 1Prednisone 1Methylprednisolone Hemisuccinate 1Injections 1Infliximab 1Cell- and Tissue-Based Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colitis × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡